Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome

Rita Ehrlich, Thomas A. Ciulla, Raj Maturi, Nisha S. Kheradiya, Nick Hrisomalos, Shiri Shulman, Matthew G. Guess, Ellen Coyle, Alon Harris

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to assess the efficacy of intravitreal bevacizumab for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome. Methods: This is a chart review of retrospective consecutive case series in which intravitreal bevacizumab (1.25 mg) was injected into 24 eyes with choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome. Visual acuity was measured in all patients. Optical coherence tomography and/or fluorescein angiography was performed before and after treatment. The minimum follow-up time was 3 months. Retreatment criteria included failure to improve visual acuity and/or persistent leakage as determined by optical coherence tomography or fluorescein angiography. Results: Patients' mean age was 43.08 years (standard deviation, 13.58 years) and mean follow-up was 31.8 weeks (standard deviation, 20.79 weeks). The average number of bevacizumab injections was 6.8 injections/year. After 3 months, visual acuity improved from mean logMAR 0.76 ± 0.48 (Snellen equivalent of 20/114) to mean logMAR 0.45 ± 0.47 (Snellen equivalent of 20/55) (P < 0.001, paired t test; n = 24). After 12 months, visual acuity improved from mean logMAR 0.86 ± 0.35 (Snellen equivalent of 20/150) to mean logMAR 0.34 ± 0.33 (Snellen equivalent of 20/45) (P = 0.006, paired t test; n = 9). Fourteen (58.3%) eyes had final visual acuity of 20/40 or better compared with 5 (20.8%) eyes at baseline (P = 0.003, McNemar test). Ten patients (41.6%) had visual acuity of 20/200 or worse at baseline compared with 5 (20.8%) eyes at the final visit (P = 0.059, McNemar test). Conclusion: Intravitreal injection of bevacizumab seems to be an effective treatment for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome.

Original languageEnglish
Pages (from-to)1418-1423
Number of pages6
JournalRetina
Volume29
Issue number10
DOIs
StatePublished - Nov 2009

Fingerprint

Histoplasmosis
Choroidal Neovascularization
Visual Acuity
Fluorescein Angiography
Optical Coherence Tomography
Intravitreal Injections
Injections
Retreatment
Bevacizumab
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome. / Ehrlich, Rita; Ciulla, Thomas A.; Maturi, Raj; Kheradiya, Nisha S.; Hrisomalos, Nick; Shulman, Shiri; Guess, Matthew G.; Coyle, Ellen; Harris, Alon.

In: Retina, Vol. 29, No. 10, 11.2009, p. 1418-1423.

Research output: Contribution to journalArticle

Ehrlich, R, Ciulla, TA, Maturi, R, Kheradiya, NS, Hrisomalos, N, Shulman, S, Guess, MG, Coyle, E & Harris, A 2009, 'Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome', Retina, vol. 29, no. 10, pp. 1418-1423. https://doi.org/10.1097/IAE.0b013e3181babdf1
Ehrlich R, Ciulla TA, Maturi R, Kheradiya NS, Hrisomalos N, Shulman S et al. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome. Retina. 2009 Nov;29(10):1418-1423. https://doi.org/10.1097/IAE.0b013e3181babdf1
Ehrlich, Rita ; Ciulla, Thomas A. ; Maturi, Raj ; Kheradiya, Nisha S. ; Hrisomalos, Nick ; Shulman, Shiri ; Guess, Matthew G. ; Coyle, Ellen ; Harris, Alon. / Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome. In: Retina. 2009 ; Vol. 29, No. 10. pp. 1418-1423.
@article{7c6b646487884a74a879a14030af9827,
title = "Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome",
abstract = "Purpose: The purpose of this study was to assess the efficacy of intravitreal bevacizumab for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome. Methods: This is a chart review of retrospective consecutive case series in which intravitreal bevacizumab (1.25 mg) was injected into 24 eyes with choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome. Visual acuity was measured in all patients. Optical coherence tomography and/or fluorescein angiography was performed before and after treatment. The minimum follow-up time was 3 months. Retreatment criteria included failure to improve visual acuity and/or persistent leakage as determined by optical coherence tomography or fluorescein angiography. Results: Patients' mean age was 43.08 years (standard deviation, 13.58 years) and mean follow-up was 31.8 weeks (standard deviation, 20.79 weeks). The average number of bevacizumab injections was 6.8 injections/year. After 3 months, visual acuity improved from mean logMAR 0.76 ± 0.48 (Snellen equivalent of 20/114) to mean logMAR 0.45 ± 0.47 (Snellen equivalent of 20/55) (P < 0.001, paired t test; n = 24). After 12 months, visual acuity improved from mean logMAR 0.86 ± 0.35 (Snellen equivalent of 20/150) to mean logMAR 0.34 ± 0.33 (Snellen equivalent of 20/45) (P = 0.006, paired t test; n = 9). Fourteen (58.3{\%}) eyes had final visual acuity of 20/40 or better compared with 5 (20.8{\%}) eyes at baseline (P = 0.003, McNemar test). Ten patients (41.6{\%}) had visual acuity of 20/200 or worse at baseline compared with 5 (20.8{\%}) eyes at the final visit (P = 0.059, McNemar test). Conclusion: Intravitreal injection of bevacizumab seems to be an effective treatment for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome.",
author = "Rita Ehrlich and Ciulla, {Thomas A.} and Raj Maturi and Kheradiya, {Nisha S.} and Nick Hrisomalos and Shiri Shulman and Guess, {Matthew G.} and Ellen Coyle and Alon Harris",
year = "2009",
month = "11",
doi = "10.1097/IAE.0b013e3181babdf1",
language = "English",
volume = "29",
pages = "1418--1423",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome

AU - Ehrlich, Rita

AU - Ciulla, Thomas A.

AU - Maturi, Raj

AU - Kheradiya, Nisha S.

AU - Hrisomalos, Nick

AU - Shulman, Shiri

AU - Guess, Matthew G.

AU - Coyle, Ellen

AU - Harris, Alon

PY - 2009/11

Y1 - 2009/11

N2 - Purpose: The purpose of this study was to assess the efficacy of intravitreal bevacizumab for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome. Methods: This is a chart review of retrospective consecutive case series in which intravitreal bevacizumab (1.25 mg) was injected into 24 eyes with choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome. Visual acuity was measured in all patients. Optical coherence tomography and/or fluorescein angiography was performed before and after treatment. The minimum follow-up time was 3 months. Retreatment criteria included failure to improve visual acuity and/or persistent leakage as determined by optical coherence tomography or fluorescein angiography. Results: Patients' mean age was 43.08 years (standard deviation, 13.58 years) and mean follow-up was 31.8 weeks (standard deviation, 20.79 weeks). The average number of bevacizumab injections was 6.8 injections/year. After 3 months, visual acuity improved from mean logMAR 0.76 ± 0.48 (Snellen equivalent of 20/114) to mean logMAR 0.45 ± 0.47 (Snellen equivalent of 20/55) (P < 0.001, paired t test; n = 24). After 12 months, visual acuity improved from mean logMAR 0.86 ± 0.35 (Snellen equivalent of 20/150) to mean logMAR 0.34 ± 0.33 (Snellen equivalent of 20/45) (P = 0.006, paired t test; n = 9). Fourteen (58.3%) eyes had final visual acuity of 20/40 or better compared with 5 (20.8%) eyes at baseline (P = 0.003, McNemar test). Ten patients (41.6%) had visual acuity of 20/200 or worse at baseline compared with 5 (20.8%) eyes at the final visit (P = 0.059, McNemar test). Conclusion: Intravitreal injection of bevacizumab seems to be an effective treatment for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome.

AB - Purpose: The purpose of this study was to assess the efficacy of intravitreal bevacizumab for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome. Methods: This is a chart review of retrospective consecutive case series in which intravitreal bevacizumab (1.25 mg) was injected into 24 eyes with choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome. Visual acuity was measured in all patients. Optical coherence tomography and/or fluorescein angiography was performed before and after treatment. The minimum follow-up time was 3 months. Retreatment criteria included failure to improve visual acuity and/or persistent leakage as determined by optical coherence tomography or fluorescein angiography. Results: Patients' mean age was 43.08 years (standard deviation, 13.58 years) and mean follow-up was 31.8 weeks (standard deviation, 20.79 weeks). The average number of bevacizumab injections was 6.8 injections/year. After 3 months, visual acuity improved from mean logMAR 0.76 ± 0.48 (Snellen equivalent of 20/114) to mean logMAR 0.45 ± 0.47 (Snellen equivalent of 20/55) (P < 0.001, paired t test; n = 24). After 12 months, visual acuity improved from mean logMAR 0.86 ± 0.35 (Snellen equivalent of 20/150) to mean logMAR 0.34 ± 0.33 (Snellen equivalent of 20/45) (P = 0.006, paired t test; n = 9). Fourteen (58.3%) eyes had final visual acuity of 20/40 or better compared with 5 (20.8%) eyes at baseline (P = 0.003, McNemar test). Ten patients (41.6%) had visual acuity of 20/200 or worse at baseline compared with 5 (20.8%) eyes at the final visit (P = 0.059, McNemar test). Conclusion: Intravitreal injection of bevacizumab seems to be an effective treatment for choroidal neovascularization resulting from presumed ocular histoplasmosis syndrome.

UR - http://www.scopus.com/inward/record.url?scp=73349132721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349132721&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e3181babdf1

DO - 10.1097/IAE.0b013e3181babdf1

M3 - Article

C2 - 19898179

AN - SCOPUS:73349132721

VL - 29

SP - 1418

EP - 1423

JO - Retina

JF - Retina

SN - 0275-004X

IS - 10

ER -